Wockhardt Ltd
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
- Market Cap ₹ 28,724 Cr.
- Current Price ₹ 1,768
- High / Low ₹ 1,804 / 552
- Stock P/E
- Book Value ₹ 170
- Dividend Yield 0.00 %
- ROCE 4.40 %
- ROE -0.53 %
- Face Value ₹ 5.00
Pros
Cons
- Stock is trading at 9.32 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.51% over past five years.
- Company has a low return on equity of -10.8% over last 3 years.
- Company has high debtors of 159 days.
- Promoter holding has decreased over last 3 years: -18.0%
- Working capital days have increased from 198 days to 303 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,805 | 1,887 | 2,217 | 2,298 | 2,477 | 1,557 | 890 | 987 | 1,372 | 1,072 | 1,154 | 1,402 | |
1,780 | 1,879 | 2,091 | 2,153 | 2,154 | 1,619 | 1,023 | 1,125 | 1,150 | 1,002 | 1,190 | 1,102 | |
Operating Profit | 25 | 7 | 126 | 145 | 323 | -62 | -133 | -138 | 222 | 70 | -36 | 300 |
OPM % | 1% | 0% | 6% | 6% | 13% | -4% | -15% | -14% | 16% | 7% | -3% | 21% |
319 | 465 | 62 | 248 | 57 | 126 | 138 | 884 | 38 | -168 | 27 | 55 | |
Interest | 34 | 19 | 108 | 169 | 170 | 171 | 220 | 200 | 273 | 229 | 237 | 199 |
Depreciation | 96 | 103 | 99 | 106 | 106 | 120 | 173 | 184 | 171 | 186 | 176 | 168 |
Profit before tax | 215 | 350 | -20 | 119 | 104 | -227 | -389 | 362 | -184 | -513 | -422 | -12 |
Tax % | 8% | 5% | -143% | -15% | 34% | -64% | -41% | -64% | -24% | -9% | 0% | 0% |
199 | 332 | 8 | 137 | 69 | -82 | -231 | 593 | -140 | -466 | -422 | -12 | |
EPS in Rs | 13.92 | 23.19 | 0.58 | 9.54 | 4.77 | -5.69 | -16.05 | 41.18 | -9.72 | -32.34 | -27.51 | -0.74 |
Dividend Payout % | 55% | 66% | 0% | 81% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -3% |
5 Years: | 10% |
3 Years: | 1% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 24% |
TTM: | 97% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 46% |
3 Years: | 85% |
1 Year: | 164% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | -1% |
3 Years: | -11% |
Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 |
Reserves | 882 | 1,016 | 1,113 | 1,164 | 1,239 | 1,171 | 939 | 1,551 | 2,140 | 1,681 | 1,719 | 2,682 |
482 | 1,138 | 1,984 | 2,120 | 1,773 | 1,885 | 2,370 | 2,078 | 2,024 | 2,013 | 2,136 | 1,796 | |
1,972 | 1,939 | 1,431 | 1,230 | 1,318 | 1,426 | 1,395 | 1,211 | 1,562 | 966 | 936 | 849 | |
Total Liabilities | 3,391 | 4,149 | 4,584 | 4,569 | 4,386 | 4,538 | 4,760 | 4,895 | 5,798 | 4,732 | 4,868 | 5,408 |
1,033 | 1,005 | 1,402 | 1,465 | 1,423 | 1,614 | 2,044 | 1,684 | 1,828 | 1,625 | 1,449 | 2,457 | |
CWIP | 582 | 792 | 664 | 665 | 653 | 381 | 305 | 716 | 825 | 823 | 833 | 79 |
Investments | 308 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 719 |
1,469 | 2,054 | 2,221 | 2,142 | 2,013 | 2,245 | 2,113 | 2,198 | 2,848 | 1,987 | 2,289 | 2,153 | |
Total Assets | 3,391 | 4,149 | 4,584 | 4,569 | 4,386 | 4,538 | 4,760 | 4,895 | 5,798 | 4,732 | 4,868 | 5,408 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
131 | -53 | -363 | -235 | 119 | 58 | 222 | -563 | -93 | 71 | 188 | -14 | |
-25 | 203 | -1,015 | 369 | 451 | 120 | -16 | 1,014 | -244 | -3 | -75 | -900 | |
-188 | 425 | 764 | -133 | -524 | -69 | -274 | -480 | 430 | -236 | 346 | 486 | |
Net Cash Flow | -81 | 575 | -614 | 1 | 46 | 109 | -69 | -29 | 93 | -168 | 459 | -428 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 50 | 41 | 45 | 54 | 118 | 236 | 385 | 353 | 344 | 188 | 179 | 159 |
Inventory Days | 221 | 240 | 216 | 206 | 141 | 195 | 367 | 305 | 297 | 330 | 254 | 357 |
Days Payable | 151 | 158 | 134 | 133 | 167 | 325 | 611 | 355 | 446 | 507 | 459 | 398 |
Cash Conversion Cycle | 120 | 123 | 126 | 127 | 92 | 105 | 141 | 303 | 194 | 11 | -26 | 117 |
Working Capital Days | -56 | -171 | 73 | 33 | 9 | 79 | 39 | 193 | 173 | 170 | 122 | 303 |
ROCE % | 18% | 20% | 3% | 9% | 9% | -2% | -5% | -8% | 2% | -1% | -4% | 4% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
5 Jun - Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended and in continuation of our letter bearing reference number WOCK/SEC/SE/2025-26/012 dated 2nd June, 2025 please find …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
5 Jun - In continuation to our letter dated 2nd June, 2025, Please find enclosed herewith a copy of Investor Presentation to be made at the Investor Meet …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Jun - The Company will hold an Investor meet/call on Thursday, 5th June, 2025 at 11:00 hrs IST through VC and in-person as detailed in the enclosed …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
29 May - Wockhardt FY25 revenue Rs 3033 Cr, EBITDA Rs 418 Cr; launched Miqnaf; Zaynich filed in India, US filing planned.
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - Wockhardt reports FY25 audited results, director re-appointment, secretarial auditor appointment, and proposes equity fund raise.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Market Position
The company is amongst the top 3 Indian generic companies in the UK and the 6th largest generic supplier in the retail and hospital channels in Ireland. It is the No. 1 Methycobalamin brand in India. [1]